Heidelberg Pharma AG

HPHA

Company Profile

  • Business description

    Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

  • Contact

    Gregor-Mendel-Street 22
    Ladenburg68526
    DEU

    T: +49 620310090

    E: [email protected]

    https://www.heidelberg-pharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 November 2025

    Employees

    122

Stocks News & Analysis

stocks

Here’s how to value a share

Our best resources to help investors determine the value of a share.
stocks

How to avoid dividend disaster

Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks

GyG punished by market after solid earnings

Although Guzman y Gomez had solid earnings, it failed to meet lofty market expectations.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,245.0045.00-0.48%
CAC 407,969.6931.400.40%
DAX 4024,363.0969.750.29%
Dow JONES (US)45,631.74846.241.89%
FTSE 1009,321.4012.200.13%
HKSE25,888.01783.403.12%
NASDAQ21,496.54396.221.88%
Nikkei 22542,807.82197.650.46%
NZX 50 Index13,079.50114.57-0.87%
S&P 5006,466.9196.741.52%
S&P/ASX 2008,972.4052.00-0.58%
SSE Composite Index3,873.8548.091.26%

Market Movers